Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
4583 On Other Exchanges
4583 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

chiome bioscience inc (4583) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHIOME BIOSCIENCE INC (4583)

Related News

No related news articles were found.

chiome bioscience inc (4583) Related Businessweek News

No Related Businessweek News Found

chiome bioscience inc (4583) Details

Chiome Bioscience Inc. is engaged in the research and development of its proprietary drug discovery platform technology worldwide. It facilitates drug discovery companies, such as drug manufacturers and biotech companies to develop antibody drugs through programs based on the autonomously diversifying library system (ADLib system). The ADLib system is a monoclonal antibody generating system that provides various arrays of antibodies in vitro, without using immunization. The company deploys the ADLib system to generate therapeutics antibodies; and licenses novel therapeutic antibodies for antigens to pharmaceutical manufactures. Chiome Bioscience Inc. was founded in 2005 and is headquartered in Tokyo, Japan.

Founded in 2005

chiome bioscience inc (4583) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

chiome bioscience inc (4583) Key Developments

Chiome Bioscience Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2015

Chiome Bioscience Inc. announced consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the consolidated company reported net sales of ¥67,551,000, operating loss of ¥351,496,000, ordinary loss of ¥350,052,000 or net loss of ¥349,299,000 or ¥15.92 per share. Loss before income taxes ¥349,862,000. For the fiscal year ending December 31, 2015, on non-consolidated basis, the company expects net sales of ¥636 million, operating loss of ¥1,908 million, ordinary loss of ¥1,907 million and net loss of ¥1,912 million or ¥87.13 per share.

Chiome Bioscience Inc. to Report Q1, 2015 Results on May 14, 2015

Chiome Bioscience Inc. announced that they will report Q1, 2015 results on May 14, 2015

Chiome Biosciences, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 03:00 PM

Chiome Biosciences, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 03:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4583:JP ¥838.00 JPY +11.00

4583 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4583.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4583 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHIOME BIOSCIENCE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at